Seth Klarman: portfolio of Baupost Group

Seth Klarman leads the Baupost Group, which follows a value approach and looks for securities trading below their estimated worth.

Source: 13F filing with the US Securities and Exchange Commission dated Aug 13, 2019. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

You are looking at Q2 2019. Go to the latest filing (Q3 2026)

10.7B USDQ2 2019
Total value of stock positions
10.7B USD
Positions
30
Share of the ten largest
72.3%

The ten largest positions Q2 2019

  1. Liberty Global PLC 10.4%▲ +7.3%
  2. Viasat Inc 10.3%unchanged
  3. Fox Corporation (Class A) 9.3%unchanged
  4. eBay Inc. 8.9%▼ −17.6%
  5. Cheniere Energy Inc 6.8%▼ −15.4%
  6. Allergan PLC 5.7%▼ −22.9%
  7. Bristol Myers Squibb 5.5%▲ +225.0%
  8. Qorvo Inc 5.4%▼ −18.0%
  9. PG&E Corporation 5.2%unchanged
  10. Cbs Corp New 4.7%▲ +17.1%
Total value of stock positions per quarter, Q2 2013 to Q3 2026 (peak 12.7B USD).
Choose a quarter (54 filings)

All positions Q2 2019

Positions Q2 2019 per 13F filing, 30 of 30
Symbol Weight Shares Reported value Change Held since
Liberty Global PLC 10.4% 41,937,674 1.1B USD +7.3% increased Q3 2018 4 quarters
Viasat Inc 10.3% 13,732,068 1.1B USD unchanged Q2 2013 or earlier 25 quarters
FOXA Fox Corporation (Class A) 9.3% 27,322,720 1.0B USD unchanged Q1 2019 2 quarters
EBAY eBay Inc. 8.9% 24,146,000 953.8M USD −17.6% reduced Q4 2018 3 quarters
Cheniere Energy Inc 6.8% 10,674,135 730.6M USD −15.4% reduced Q1 2014 22 quarters
Allergan PLC 5.7% 3,679,549 616.1M USD −22.9% reduced Q1 2016 14 quarters
BMY Bristol Myers Squibb 5.5% 13,000,000 589.6M USD +225.0% increased Q1 2019 2 quarters
Qorvo Inc 5.4% 8,681,181 578.3M USD −18.0% reduced Q1 2017 10 quarters
PCG PG&E Corporation 5.2% 24,500,000 561.5M USD unchanged Q1 2018 6 quarters
Cbs Corp New 4.7% 10,000,000 499.0M USD +17.1% increased Q4 2018 3 quarters
MCK McKesson Corporation 3.3% 2,595,011 348.7M USD −7.8% reduced Q3 2017 8 quarters
SYF Synchrony Financial 3.0% 9,260,557 321.1M USD −35.1% reduced Q3 2016 12 quarters
Colony Cap Inc New 2.3% 49,687,370 248.4M USD unchanged Q2 2018 5 quarters
Univar Inc 2.0% 9,500,000 209.4M USD unchanged Q3 2018 4 quarters
FOX Fox Corporation (Class B) 1.9% 5,680,307 207.5M USD unchanged Q1 2019 2 quarters
Liberty Global PLC 1.9% 7,440,705 200.8M USD +50.1% increased Q3 2018 4 quarters
COR Cencora 1.8% 2,214,192 188.8M USD −7.9% reduced Q3 2017 8 quarters
Takeda Pharmaceutical Co Ltd 1.6% 9,438,003 167.1M USD −11.5% reduced Q1 2019 2 quarters
Antero Res Corp 1.5% 28,587,791 158.1M USD unchanged Q3 2014 20 quarters
Theravance Biopharma Inc 1.4% 9,309,168 152.0M USD unchanged Q2 2014 21 quarters
Nexstar Media Group Inc 1.3% 1,397,755 141.2M USD +39.8% increased Q4 2018 3 quarters
Atara Biotherapeutics Inc 1.3% 7,000,000 140.8M USD +9.7% increased Q4 2014 19 quarters
Akebia Therapeutics Inc 1.1% 24,471,453 118.4M USD unchanged Q4 2018 3 quarters
Translate Bio Inc 1.0% 8,844,239 109.4M USD +36.2% increased Q2 2018 5 quarters
Xpo Logistics Inc 0.8% 1,500,000 86.7M USD new Q2 2019 1 quarter
Veritiv Corp 0.6% 3,564,439 69.2M USD unchanged Q3 2014 20 quarters
Trilogy Metals Inc New 0.4% 13,641,368 39.8M USD +4.5% increased Q3 2016 12 quarters
Sinclair Broadcast Group Inc 0.3% 549,423 29.5M USD −81.1% reduced Q2 2018 5 quarters
Gossamer Bio Inc 0.3% 1,267,171 27.3M USD unchanged Q1 2019 2 quarters
Paratek Pharmaceuticals Inc < 0.1% 2,394,498 9.6M USD unchanged Q4 2014 19 quarters

“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.

Plus 2 positions in convertible bonds and bonds worth 321.3M USD as reported – not included in the weights.

Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.

  • Tesla Inc principal 300.0M USD 295.5M USD
  • Theravance Biopharma Inc principal 30.0M USD 25.7M USD

Breakdown by sector

  • Communication Services 11.3%
  • Health Care 10.5%
  • Consumer Discretionary 8.9%
  • Utilities 5.2%
  • Financials 3.0%
  • not in our coverage 61.1%

Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.

How to read this page

  • Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
  • Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
  • Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.

All superinvestor portfolios Screener: stocks held by superinvestors

↑ ↓ select · Enter open · Esc close